HealthEquity (HQY) to Release Quarterly Earnings on Tuesday

Key Points

• HealthEquity is set to announce its Q2 2026 earnings on September 2nd, with expected earnings of $0.92 per share and revenue of $320.68 million.
• The company's previous earnings results showed earnings of $0.97 per share, surpassing analyst expectations by $0.16, and revenue of $330.8 million against estimates of $322.25 million.
• Several analysts have increased their target prices for HealthEquity, with an average target price of $118.55 and multiple "buy" ratings from leading investment firms.

HealthEquity (NASDAQ:HQY - Get Free Report) will likely be announcing its Q2 2026 results after the market closes on Tuesday, September 2nd. Analysts expect the company to announce earnings of $0.92 per share and revenue of $320.6840 million for the quarter. HealthEquity has set its FY 2026 guidance at 3.610-3.78 EPS.Investors may visit the the company's upcoming Q2 2026 earningresults page for the latest details on the call scheduled for Tuesday, September 2, 2025 at 4:30 PM ET.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. The firm had revenue of $330.80 million during the quarter, compared to analyst estimates of $322.25 million. During the same period in the prior year, the business earned $0.80 EPS. On average, analysts expect HealthEquity to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

HealthEquity Trading Down 2.7%

HealthEquity stock opened at $87.42 on Tuesday. The firm has a 50-day moving average of $96.50 and a 200-day moving average of $96.26. HealthEquity has a one year low of $73.84 and a one year high of $116.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.06 and a quick ratio of 4.06. The company has a market cap of $7.56 billion, a price-to-earnings ratio of 63.81, a P/E/G ratio of 1.39 and a beta of 0.54.

Insider Buying and Selling

In related news, Director Jon Kessler sold 134,183 shares of HealthEquity stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.08, for a total transaction of $15,039,230.64. Following the completion of the transaction, the director owned 253,510 shares of the company's stock, valued at $28,413,400.80. This trade represents a 34.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Henry Fiore sold 1,794 shares of HealthEquity stock in a transaction on Monday, July 7th. The shares were sold at an average price of $101.73, for a total transaction of $182,503.62. Following the completion of the sale, the executive vice president directly owned 53,225 shares of the company's stock, valued at approximately $5,414,579.25. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 291,744 shares of company stock valued at $32,705,007 over the last quarter. Insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On HealthEquity

Hedge funds and other institutional investors have recently made changes to their positions in the business. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of HealthEquity during the second quarter worth about $217,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of HealthEquity during the second quarter worth about $273,000. Orion Porfolio Solutions LLC increased its position in shares of HealthEquity by 14.9% during the second quarter. Orion Porfolio Solutions LLC now owns 3,770 shares of the company's stock worth $395,000 after acquiring an additional 490 shares in the last quarter. Jump Financial LLC bought a new stake in shares of HealthEquity during the second quarter worth about $449,000. Finally, Corient Private Wealth LLC purchased a new position in HealthEquity during the second quarter worth about $518,000. 99.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America raised their target price on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Royal Bank Of Canada raised their target price on shares of HealthEquity from $112.00 to $117.00 and gave the company an "outperform" rating in a research note on Wednesday, June 4th. JMP Securities increased their price target on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a report on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $98.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, June 5th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $120.00 price target (up from $115.00) on shares of HealthEquity in a report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $118.55.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.